CSL to expand, create 333 jobs

Australia's CSL is getting a boost from the Victorian government, which is backing the company's expansion of its Broadmeadows facility--a move that will create 333 new jobs by 2018, according to a statement.  

The facility currently develops vaccines, but the investment focus on supporting new research into cancer, blood disorders, inflammation, infection and developing drugs for clinical trials, The Age reports. CSL's investment will include enhancements to the site to support the integration of the new biotech facility and to ensure it has the appropriate infrastructure to cater for expanded activities into the future.

The company markets it products in the Australian and international markets and employees roughly 10,000 people in 27 countries, including about 1,500 in Victoria.

"Today's announcement is great news for jobs, great news for the local economy and is a great example of what can be achieved through partnerships between government and the private sector," Premier John Brumby says in a statement. "Victoria has earned itself a reputation as the biotech hub of the Asia-Pacific and we are well on the way to becoming one of the world's top five biotech destinations."

- see the Victorian government's statement
- read more from CSL
- get more from The Age

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.